Literature DB >> 3121202

The binding of thio-TEPA in human serum and to isolated serum protein fractions.

B Hagen1, O G Nilsen.   

Abstract

Binding of triethylenethiophosphoramide (thio-TEPA) in serum from healthy individuals and from cancer patients and its binding to isolated serum protein fractions were studied by equilibrium dialysis. A drug-protein binding in the order of 10% was demonstrated in serum, with little interindividual variation. The protein binding of thio-TEPA seemed to be restricted to albumin and lipoproteins, with the greatest affinity to albumin. The previously reported selective binding of thio-TEPA to gamma globulin was contrary to our findings. The almost insignificant degree of serum protein binding of thio-TEPA indicates that the drug is well suited for use in cancer drug combinations.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3121202     DOI: 10.1007/bf00262584

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  7 in total

1.  Investigation of distribution and excretion of C14 tagged triethylene thiophosphoramide following injection by various routes.

Authors:  J C BATEMAN; H N CARLTON; R C CALVERT; G E LINDENBLAD
Journal:  Int J Appl Radiat Isot       Date:  1960-02

2.  Human plasma pharmacokinetics and urinary excretion of thiotepa and its metabolites.

Authors:  B E Cohen; M J Egorin; E A Kohlhepp; J Aisner; P L Gutierrez
Journal:  Cancer Treat Rep       Date:  1986-07

3.  Gas chromatographic assay of triethylenethiophosphoramide in serum and urine.

Authors:  B Hagen; F Walseth; R A Walstad; T Iversen
Journal:  J Chromatogr       Date:  1985-11-29

Review 4.  Disease-induced changes in the plasma binding of basic drugs.

Authors:  K M Piafsky
Journal:  Clin Pharmacokinet       Date:  1980 May-Jun       Impact factor: 6.447

5.  Gas chromatographic analysis of triethylenethiophosphoramide and triethylenephosphoramide in biological specimens.

Authors:  B J McDermott; J A Double; M C Bibby; D E Wilman; P M Loadman; R L Turner
Journal:  J Chromatogr       Date:  1985-03-22

6.  Single and repeated dose pharmacokinetics of thio-TEPA in patients treated for ovarian carcinoma.

Authors:  B Hagen; F Walseth; R A Walstad; T Iversen; O G Nilsen
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

7.  Pharmacokinetic basis for the comparative antitumour activity and toxicity of chlorambucil, phenylacetic acid mustard and beta, beta-difluorochlorambucil (CB 7103) in mice.

Authors:  F Y Lee; P Coe; P Workman
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

  7 in total
  2 in total

1.  Population pharmacokinetics of thioTEPA and its active metabolite TEPA in patients undergoing high-dose chemotherapy.

Authors:  A D Huitema; R A Mathôt; M M Tibben; J H Schellens; S Rodenhuis; J H Beijnen
Journal:  Br J Clin Pharmacol       Date:  2001-01       Impact factor: 4.335

2.  ThioTEPA pharmacokinetics during intravesical chemotherapy and the influence of Tween 80.

Authors:  J R Masters; B J McDermott; W E Jenkins; E Fenwick; P J Shah; A R Mundy; P M Loadman; M C Bibby
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.